Member Info for evman27

Fill or kill to buy.

we move on very little volume here.

MMs at their usual games.

Sellers gunna sell eh

Good to see smart buyers loading up after that dip.

Not a sell the news RNS at all, expanding of patents into Asia market is highly encouraging.

Protects Fusions IP on their, ‘Worlds first’ platform more globally and makes them more attractive for a potential takeover offer, with wider protection in place.

Adrian has just answered a lot of questions on the Hub, I would encourage new investors to sign up on their website and navigate to past RNSs where you can see the answers and ask the company questions directly.

Although yet to be RNSd, we now know that Optimal is protected by patent. The scientist board are now ready to promote it.

This just posted on FABs LinkedIn,

https://www.linkedin.com/posts/richardbuick_antibodyengineering-antibodytherapeutics-activity-7353992250000818177-m-pX/?utm_source=share&utm_medium=member_ios&rcm=ACoAACft1F0BaVDaXIBn7r_8No_nNgqdtyRaz0w

Richard is a great guy and a true professional, he has been with Fusion since 2002.

The subject of his presentation is the following.

OptiMAL™: Mammalian Display of a Human IgG Library for Discovery of Novel Antibodies

OptiMAL™ represents the World's first platform using a fully synthetic human antibody library that can be screened using Mammalian Display in the native IgG format. The results shown will demonstrate that this platform can be used for the discovery of antibodies with high specificity, developability and yield, in a competitive timeframe. Followed by the knowledge that a rationally designed synthetic library can out-perform more traditional library design methods.

https://informaconnect.com/antibody-engineering-therapeutics/speakers/richard-buick-phd/#scientific-luncheon-briefing-1_optimal-mammalian-display-of-a-human-igg-library-for-discovery-of-novel-antibodies

Read the summary again and again and it's almost impossible to NOT be bullish on Fusions future.

The collaboration with the NCI, which I assume has concluded with full validation given the affirmed content of Richards presentation, combined with yesterdays patent news is the start of the promotion for what I see as a very bright future for FAB.

Here here Sean.

SST1

Would you please name and shame the accounts you suspect as rampers with multiple accounts?

Yeah I'm backing my guy Vick, He does a lot of charity work in his local community, great guy keep it up Vick!

Yeah no one likes to see sellers do they, but its healthy for the gradual climb, so I take it with a pinch of salt.

I think traders love this kind of share because of how quick it moves, I don't read into that too much.

Jollifant, Fusion has long sat massively undervalued for many years, we are at an inflection point in the company where the market is just waking up to their potential.

I would suggest buyers hold their shares long on this one.

Small float and a full magazine of news just waiting to fire out.

It has all the ingredients for big returns for long holders.

GLA

Vikr you deserve a prize for your motivation speeches.

MMs shake in their boots as Vikrs booming commands rain down the hills.

Nice to see a few new faces on here, welcome.

Little healthy pullbak again but can you really complain on a 20% day?

Nope!

NewboF wins the 1000 share competition!

Anyway, fantastic progress with the patent, another step further for Fusion and another layer of risk shaved off.

Just goes to show that the PIs who have been chatting for the past weeks on this board do their homework, top marks!

Well I would assume it’s also close, the NCI collaboration is ending in November with a clear safety net part of that, after all we are dealing with scientists. I assume journals are also being put together as we speak. We know it works, that’s not a problem, they even let it slip and called optimal validated in the investor meet.

That’s why I believe once the patent has landed that it will be the catalyst for a barrage of news flow.

I’d just like to add that the patent is just the beginning for Fusion, definitely not a sell the news type item.

I’m waiting for the ‘step changes’ and Adrian unloading his ‘sleeves’

It really is super close isn’t it!

I’ve been refreshing the website flat out.

https://patentcenter.uspto.gov/applications/17287441/ifw/transactions?application=

Whoever posts confirmation here too wins 1000 FAB shares from me, I’m sure darkryder will chuck in another 7 if he’s feeling generous.

Here is the link so you can join me too!

Once the parent lands I’m sure of steady news flow, still currently undervalued.

I have no intention of selling for pennies, this company is going through step changes back to where it belongs.

Healthy pullback, weak hands shaken out, no concerns here.

Livinhope, I agree, a little test of 10 today very much on the cards.

Ah GTC you reminded me about this, thanks.

Another consortium we have recently found out about that Fusion are partners of is ‘SABS R³’, ‘Sustainable Approaches to Biomedical Science’

This consortium is doctoral training programme at the University of Oxford.

Fusion recently posted about it on LinkedIn.

https://www.linkedin.com/posts/fusion-antibodies-plc_fusion-antibodies-had-the-pleasure-of-welcoming-activity-7348751743150706689-1eXr/?utm_source=share&utm_medium=member_ios&rcm=ACoAAAuyH_0BZuiiVe69ogYIdwe7HKyUbPvkmaA

There are some very big names in this consortium, Roche, Merck and AstraZeneca just to name a few.

https://www.sabsr3.ox.ac.uk/partners

Although this consortium isn’t necessarily a big revenue driver, It is important to recognise that FAB’s MCAP is small in this group (£8m), but the work they do is highly regarded in the pharma industry. They have been invited to sit at the table with the likes of Merck ($200.8 billion) to educate at the University of Oxford.

To me, this is a big sign of respect and foreshadows where Fusion could be in the coming months and years.

Sure what else would you been doing on a Sunday night stt1?

I've just logged in to see what has been a week of super constructive conversation on Fusion Antibodies prospects.

Unsurprisingly, with any rise, the derampers have arrived....

A quick history browse and it doesn't take long to see 'stt1' cannot string a positive sentence together for any company, even if his life depended on it!

STT1 - I wish you all the best.

I'm glad you have mentioned OptiPhage™, we sometimes forget about that project given the excitement around OptiMAL®.

They also have proprietary platforms like CDRx®, ADD™, RAMP®.

It just shows how diverse Fusions business model is in the antibody market.

Given the BOD is full of experienced and cautious scientists, my suspicion is that the BOD see the patent for OptiMAL® being secured in the public domain as the first step before a flow of good news and the 'step changes' for the business that the CEO talked about.

Looking at similar timelines from the patent office in other examples, I am increasingly confident that this item is very close.

As Sean mentioned, ‘Fusions strategy is to help clients get drug candidates to the clinic faster’.

Fusion Antibodies getting their Optimal platform validated by the National Cancer Institute (NCI) comes with a wide range of benefits.

These benefits will be solely Fusions to reap as the imminent patent protecting their work is presented to the market in due course.

Here are some of the key benefits that come from NCI validation:

Increased Credibility and Scientific Validation

• Third-party validation from a respected body like the NCI provides strong scientific backing. Signals to investors, collaborators, and the broader biotech community that the platform meets high standards.

Enhanced Partnering Opportunities

• Biopharma companies are more likely to license or partner with validated platforms. This increases appeal to large pharmaceutical companies for co-development or commercialisation deals.

Competitive Differentiation

• Offers a unique selling point over competitors with unvalidated platforms. Helps distinguish Fusion Antibodies in a crowded therapeutic antibody development space.

Boosted Market Perception and Share Value

• Public companies often see increased valuation and stock price movement following such endorsements. It also enhances overall company reputation and visibility.

Accelerated Clinical Development

• Platform validation may streamline preclinical and early clinical development processes. It also makes regulatory submissions more robust.

Superb week for Fusion Antibodies.

Great to see PIs waking up to the massive potential here.

Have a FAB weekend all, catch you Monday bright and early.